These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12774055)

  • 1. IL-2 does not enhance the conversion to complete donor chimerism following nonmyeloablative hematopoietic cell transplantation in dogs.
    Georges GE; Storb R; Maciej Zaucha J; Taranova AG; Gooley T; Nash RA
    Bone Marrow Transplant; 2003 Jun; 31(11):1027-31. PubMed ID: 12774055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation.
    Georges GE; Storb R; Thompson JD; Yu C; Gooley T; Bruno B; Nash RA
    Blood; 2000 May; 95(10):3262-9. PubMed ID: 10807798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.
    Mapara MY; Kim YM; Marx J; Sykes M
    Transplantation; 2003 Jul; 76(2):297-305. PubMed ID: 12883182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy against kidney targets in dog-leukocyte antigen-identical mixed hematopoietic canine chimeras.
    Junghanss C; Takatu A; Little MT; Maciej Zaucha J; Zellmer E; Yunusov M; Sale G; Georges GE; Storb R
    Transplantation; 2003 Feb; 75(3):268-74. PubMed ID: 12589144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia.
    Takatu A; Nash RA; Zaucha JM; Little MT; Georges GE; Sale GE; Zellmer E; Kuhr CS; Lothrop CD; Storb R
    Biol Blood Marrow Transplant; 2003 Nov; 9(11):674-82. PubMed ID: 14652850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model.
    Fukuda T; Kerbauy FR; Gooley T; Santos EB; Storb R; Sandmaier BM
    Transplantation; 2006 Aug; 82(3):332-9. PubMed ID: 16906030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation.
    Baron F; Sandmaier BM; Zellmer E; Sorror M; Storer B; Storb R
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):813-7. PubMed ID: 16864051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism.
    Graves SS; Hogan WJ; Kuhr C; Diaconescu R; Harkey M; Sale GE; Stone B; Georges GE; Storb R
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1201-8. PubMed ID: 18940673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor Lymphocyte Infusion-Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation.
    Duran-Struuck R; Matar AJ; Crepeau RL; Teague AGS; Horner BM; Pathiraja V; Spitzer TR; Fishman JA; Bronson RT; Sachs DH; Huang CA
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1953-1960. PubMed ID: 27543159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of sensitized donor lymphocyte infusion on the chimerism and graft-versus-host disease after nonmyeloablative allogeneic stem cell transplantation].
    Chen BA; Zhang Y; Ding JH; Bi YZ; Zhao G; Gao C; Sun YY; Sun XM; Wang J; Chen NN; Cheng J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):102-6. PubMed ID: 16584602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism.
    Johnson BD; Taylor PA; Stankowski MC; Talib S; Hearst JE; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(11):581-7. PubMed ID: 12463476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.
    Storb R; Yu C; Wagner JL; Deeg HJ; Nash RA; Kiem HP; Leisenring W; Shulman H
    Blood; 1997 Apr; 89(8):3048-54. PubMed ID: 9108426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
    Saito TI; Rubio MT; Sykes M
    Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model.
    Zaucha JM; Yu C; Zellmer E; Takatu A; Junghanss C; Little MT; Storb R
    Biol Blood Marrow Transplant; 2001; 7(9):513-6. PubMed ID: 11669218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
    Maris M; Storb R
    Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonmyeloablative transplants: preclinical and clinical results.
    Sandmaier BM; McSweeney P; Yu C; Storb R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):78-81. PubMed ID: 10877058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant.
    Storb R; Yu C; Zaucha JM; Deeg HJ; Georges G; Kiem HP; Nash RA; McSweeney PA; Wagner JL
    Blood; 1999 Oct; 94(7):2523-9. PubMed ID: 10498626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.